Department of Gastroenterology, Daping Hospital, Army Medical University, Chongqing, China.
Helicobacter. 2024 Jul-Aug;29(4):e13079. doi: 10.1111/hel.13079.
Eradicating Helicobacter pylori infection by bismuth quadruple therapy (BQT) is effective. However, the effect of BQT and subsequent fecal microbiota transplant (FMT) on the gut microbiota is less known.
This prospective randomized controlled trial was conducted at a tertiary hospital in China from January 2019 to October 2020, with the primary endpoints the effect of BQT on the gut microbiota and the effect of FMT on the gut microbiota after bismuth quadruple therapy eradication therapy. A 14-day BQT with amoxicillin and clarithromycin was administered to H. pylori-positive subjects, and after eradication therapy, patients received a one-time FMT or placebo treatment. We then collected stool samples to assess the effects of 14-day BQT and FMT on the gut microbiota. 16 s rDNA and metagenomic sequencing were used to analyze the structure and function of intestinal flora. We also used Gastrointestinal Symptom Rating Scale (GSRS) to evaluate gastrointestinal symptom during treatment.
A total of 30 patients were recruited and 15 were assigned to either FMT or placebo groups. After eradication therapy, alpha-diversity was decreased in both groups. At the phylum level, the abundance of Bacteroidetes and Firmicutes decreased, while Proteobacteria increased. At the genus level, the abundance of beneficial bacteria decreased, while pathogenic bacteria increased. Eradication therapy reduced some resistance genes abundance while increased the resistance genes abundance linked to Escherichia coli. While they all returned to baseline by Week 10. Besides, the difference was observed in Week 10 by the diarrhea score between two groups. Compared to Week 2, the GSRS total score and diarrhea score decreased in Week 3 only in FMT group.
The balance of intestinal flora in patients can be considerably impacted by BQT in the short term, but it has reverted back to baseline by Week 10. FMT can alleviate gastrointestinal symptoms even if there was no evidence it promoted restoration of intestinal flora.
铋四联疗法(BQT)根除幽门螺杆菌感染是有效的。然而,BQT 及其随后的粪便微生物群移植(FMT)对肠道微生物群的影响知之甚少。
这项前瞻性随机对照试验于 2019 年 1 月至 2020 年 10 月在中国的一家三级医院进行,主要终点是 BQT 对肠道微生物群的影响以及 BQT 根除治疗后 FMT 对肠道微生物群的影响。对幽门螺杆菌阳性患者给予 14 天的阿莫西林和克拉霉素 BQT,根除治疗后,患者接受一次 FMT 或安慰剂治疗。然后我们收集粪便样本,以评估 14 天 BQT 和 FMT 对肠道微生物群的影响。使用 16s rDNA 和宏基因组测序分析肠道菌群的结构和功能。我们还使用胃肠道症状评分量表(GSRS)评估治疗期间的胃肠道症状。
共招募了 30 名患者,其中 15 名被分配到 FMT 或安慰剂组。根除治疗后,两组的 alpha 多样性均降低。在门水平上,拟杆菌门和厚壁菌门的丰度降低,而变形菌门的丰度增加。在属水平上,有益菌的丰度降低,而致病菌的丰度增加。根除治疗降低了一些耐药基因的丰度,同时增加了与大肠杆菌相关的耐药基因的丰度。然而,所有这些在第 10 周都恢复到基线。此外,第 10 周时两组之间腹泻评分的差异也观察到。与第 2 周相比,第 3 周时 FMT 组的 GSRS 总分和腹泻评分下降。
短期内 BQT 会对患者的肠道菌群平衡产生相当大的影响,但到第 10 周时已恢复到基线。即使没有证据表明 FMT 促进了肠道菌群的恢复,它也能缓解胃肠道症状。